Diabetes company Diamyd Medical have reported that its new diabetes drug is proving to be efficient in preserving beta cell function amongst type 2 diabetic patients.
The drug, Diamyd, the first of its type, performed well in phase 2 trials . This series of results comes at the 30-month timepoint. Diamyd had previously been proved efficient after 15 and 21 months.
The drug, termed as a therapeutic diabetes vaccine, also aided in specific immune response. The study was conduced at eight different sites in Swede, and included 70 patients. Those who were treated with Diamyd showed significant preservation of insulin secretion over a 30 month period.
The CEO and president of Diamyd Medical, Elisabeth Lindner, reportedly commented: “The plan is now to commence Phase III studies in order to confirm the positive results and then to apply for registration of the product.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…